Adlai Nortye Group Ltd. – Filings and Transcripts

NASDAQ: ANL
Share price (11/9/26): $11.15
Market cap (11/9/26): $718 million

Warning: Large portions of this site require JavaScript enabled in order to function properly. Please make sure JavaScript is enabled in your browser.

Please let us know at support@bamsec.com if you have any questions or concerns.

Search in Documents

Key Exhibits

External Links

Financials Filter

ended 12/31/25 FY 2025

ended 12/31/24 FY 2024 – amended

ended 12/31/24 FY 2024

ended 12/31/23 FY 2023 – amended

ended 12/31/23 FY 2023

Prospectuses and Registrations Filter

Amendment to registration of securities for employees

Amendment to registration of securities for employees

Updated info for already-effective prospectus

Prospectus with selling stockholder info

Shelf registration – amended

Ownership Filter

Venrock Healthcare Capital Partners III, L.P.

News Filter

Announces Oral Presentation for AN4035 Program Update at the Upcoming 38th EORTC-NCI-AACR Symposium

Enters Into Clinical Collaboration With Lilly and Merck KGaA, Darmstadt, Germany to Evaluate Combination of AN4035 and Cetuximab

Appoints Christopher Liu, PharmD, as Head of Investor Relations and Public Relations

Results of the September 30, 2026 Extraordinary General Meeting

Announces First Patient Dosed in Australia and U.S. FDA IND Clearance for AN4035, a First-In-Class Pan-Ras(On) Inhibitor-Based ADC

Proxies

No filings in this category.

Other Filter

Notice of effectiveness

Notice of effectiveness

Correspondence with the SEC

Letter from the SEC

Letter from the SEC